Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Mesylan imatynibu i chemioterapia skojarzona w leczeniu pacjentów z nowo rozpoznaną ostrą białaczką limfoblastyczną z chromosomem Philadelphia

30 września 2026 zaktualizowane przez: Children's Oncology Group

Międzynarodowe badanie fazy 3 w Filadelfii z chromosomalną ostrą białaczką limfoblastyczną (Ph+ALL) Testowanie imatinibu w połączeniu z dwoma różnymi szkieletami chemioterapii cytotoksycznej

This randomized phase III trial studies how well imatinib mesylate works in combination with two different chemotherapy regimens in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). Imatinib mesylate has been shown to improve outcomes in children and adolescents with Philadelphia chromosome positive (Ph+) ALL when given with strong chemotherapy, but the combination has many side effects. This trial is testing whether a different chemotherapy regimen may work as well as the stronger one but have fewer side effects when given with imatinib. The trial is also testing how well the combination of chemotherapy and imatinib works in another group of patients with a type of ALL that is similar to Ph+ ALL. This type of ALL is called "ABL-class fusion positive ALL", and because it is similar to Ph+ ALL, is thought it will respond well to the combination of agents used to treat Ph+ ALL.

Przegląd badań

Szczegółowy opis

PRIMARY OBJECTIVE:

I. To compare disease-free survival (DFS) of standard risk (SR) pediatric Philadelphia chromosome (Ph)+ acute lymphoblastic leukemia (ALL) treated with continuous imatinib mesylate (imatinib) combined with either a high-risk Children's Oncology Group (COG) ALL chemotherapy backbone or the more intensive European (Es)PhALL chemotherapy backbone.

SECONDARY OBJECTIVES:

I. To compare DFS of SR pediatric Ph+ and ABL-class fusion positive ALL patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone.

II. To determine the feasibility of administration of imatinib after allogeneic hematopoietic stem cell transplantation (HSCT) in high risk (HR) Ph+ ALL patients.

III. To determine event-free survival (EFS) of HR pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission and post-HSCT imatinib.

IV. To compare rates of grade 3 or higher infections in standard risk (SR) Ph+ ALL patients between the two randomized arms.

V. To evaluate EFS and overall survival (OS) of all eligible Ph+ALL patients enrolled on the study.

VI. To evaluate OS in SR Ph+ ALL patients. VII. To evaluate OS in HR Ph+ ALL patients. VIII. To evaluate EFS and OS of all eligible ABL-class fusion positive ALL patients enrolled on the study.

EXPLORATORY OBJECTIVES:

I. To describe the toxicities associated with post-HSCT administration of imatinib in HR Ph+ALL patients.

II. To evaluate the long-term toxicities in SR Ph+ ALL patients treated with chemotherapy plus imatinib (no transplant), overall and between both randomized arms.

III. To determine prognostic significance of minimal residual disease (MRD) in Ph+ ALL at various time points during therapy.

IIIa. To evaluate MRD in HR patients just prior to HSCT and then at regular intervals post-HSCT and explore the association of these measurements with long-term outcome.

IIIb. To evaluate concordance of MRD assessments made by IGH-T cell receptor (TCR) polymerase chain reaction (PCR) assay and next generation sequencing (NGS) assays.

IV. To determine and validate if IKZF1 deletions alone (IKZF1del) or with other transcription factor deletions (ie, IKZF1 plus subtype [IKZF1plus]) or other identified genetic lesions predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631.

V. To determine the frequency and prognostic significance of p190 and p210 BCR::ABL1 fusion variants in pediatric Ph+ ALL/ABL-class Ph-like ALL.

VI. To measure adherence to oral chemotherapeutic agents (imatinib, 6-mercaptopurine and methotrexate) during the maintenance phase in SR Ph+ ALL patients.

VIa. To identify factors associated with poor adherence. VIb. To determine association between relapse risk and adherence to each oral chemotherapeutic agent (separately and combined).

VII. To measure adherence to imatinib after allogeneic HSCT in HR Ph+ ALL patients and identify factors associated with poor adherence.

VIII. To compare DFS of SR ABL-class fusion positive ALL patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone.

IX. Other secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable, will be evaluated in ABL-class fusion positive ALL patients.

X. Secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable and feasible, will be evaluated in the super set of Ph+ and ABL-class fusion positive ALL patients.

XI. To determine the potential therapeutic impact of major secondary events via pharmacologic inhibitor screens in existing/engineered cell models of Ph+ and ABL-class Ph-like ALL harboring secondary events and to test the in vivo activity of the most compelling candidate compounds from pilot studies using patient-derived xenograft (PDX) models established from Ph+ and ABL-class Ph-like ALL samples collected from patients treated on AALL1631.

XII. To decipher the molecular and cellular heterogeneity of chronic myelogenous leukemia (CML)-like versus typical Ph+ ALL via single-cell genomics and functional assays and investigate CML-like phenotypes via single-cell ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) sequencing to identify distinct transcriptomic and mutational profiles that will provide novel opportunities for diagnostic and therapeutic interventions.

OUTLINE:

INDUCTION IA PART 1: Patients receive induction IA according to standard of care on days 1-14.

INDUCTION IA PART 2: Patients receive imatinib mesylate orally (PO) once daily (QD) or twice daily (BID) on days 15-33, prednisolone PO twice daily (BID) or methylprednisolone intravenously (IV) on days 15-28, vincristine sulfate IV over 1 minute on days 15 and 22, daunorubicin hydrochloride IV over 1-15 minutes on days 15 and 22, and methotrexate intrathecally (IT) on day 29.

INDUCTION IB: Patients receive imatinib mesylate PO QD or BID on days 1-35, cyclophosphamide IV over 30-60 minutes on days 1 and 28, mercaptopurine PO on days 1-28, cytarabine IV or subcutaneously (SC) on days 3-6, 10-13, 17-20, and 24-27, and methotrexate IT on days 10 and 24.

POST-INDUCTION THERAPY: Patients classified as standard risk are randomized to 1 of 2 arms. Patients with high risk are assigned to Arm C.

ARM A (SR patients assigned to ARM A):

CONSOLIDATION BLOCK 1: Patients receive imatinib mesylate PO QD or BID on days 1-21, methotrexate IT, cytarabine IT, and therapeutic hydrocortisone IT on day 1, high dose methotrexate IV over 24 hours on day 1, vincristine sulfate IV over 1 minute on days 1 and 6, dexamethasone PO BID or IV on days 1-5, cyclophosphamide IV over 30-60 minutes on days 2-4, leucovorin calcium or levoleucovorin PO or IV on days 3 and 4, high dose cytarabine IV over 3 hours and pegaspargase or calaspargase pegol IV over 1-2 hours on day 5, and filgrastim SC or IV on days 7-11 in the absence of disease progression or unexpected toxicity.

CONSOLIDATION BLOCK 2: Patients receive imatinib mesylate PO QD or BID on days 1-21, methotrexate IT, cytarabine IT, and therapeutic hydrocortisone IT on day 1, high dose methotrexate IV over 24 hours on day 1, dexamethasone PO BID or IV on days 1-5, vincristine sulfate IV over 1 minute on days 1 and 6, ifosfamide IV over 1 hour on days 2-4, leucovorin calcium or levoleucovorin PO or IV on days 3 and 4, dexrazoxane hydrochloride IV over 15 minutes and daunorubicin hydrochloride IV over 1-15 minutes on day 5, pegaspargase or calaspargase pegol IV over 1-2 hours on day 6, and filgrastim SC or IV on days 7-11 in the absence of disease progression or unexpected toxicity.

CONSOLIDATION BLOCK 3: Patients receive imatinib mesylate PO QD or BID on days 1-21, high dose cytarabine IV over 3 hours on days 1-3, dexamethasone PO BID or IV on days 1-5, etoposide IV over 1-2 hours on days 3-5, methotrexate IT, cytarabine IT, and therapeutic hydrocortisone IT on day 5, pegaspargase or calaspargase pegol IV over 1-2 hours on day 6, and filgrastim SC or IV on days 7-11 in the absence of disease progression or unexpected toxicity.

DELAYED INTENSIFICATION 1 PART 1: Patients receive imatinib mesylate PO QD or BID on days 1-35, methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 15 minutes, and doxorubicin IV over 3-15 minutes on days 8, 15, 22, and 29, and pegaspargase or calaspargase pegol IV over 1-2 hours on day 8 in the absence of disease progression or unexpected toxicity.

DELAYED INTENSIFICATION 1 PART 2: Patients receive imatinib mesylate PO QD on days 36-63, cyclophosphamide IV over 30-60 minutes on day 36, thioguanine PO on days 36-49, cytarabine IV over 1-30 minutes or SC on days 38-41 and 45-48, and methotrexate IT on days 38 and 45in the absence of disease progression or unexpected toxicity.

INTERIM MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-28, methotrexate PO on days 1, 8, 15, and 22, and mercaptopurine PO on days 1-28 in the absence of disease progression or unexpected toxicity.

DELAYED INTENSIFICATION 2 PART 1: Patients receive imatinib mesylate PO QD or BID on days 1-35, methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 15 minutes, and doxorubicin IV over 3-15 minutes on days 8, 15, 22, and 29, and pegaspargase or calaspargase pegol IV over 1-2 hours on day 8 in the absence of disease progression or unexpected toxicity.

DELAYED INTENSIFICATION 2 PART 2: Patients receive imatinib mesylate PO QD on days 36-49, cyclophosphamide IV over 30-60 minutes on day 36, thioguanine PO on days 36-49, cytarabine IV over 1-30 minutes or SC on days 36-39 and 43-46, and methotrexate IT on days 36 and 43 in the absence of disease progression or unexpected toxicity.

MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-84, methotrexate PO once weekly (QW) and IT on days 1 and 43 of cycles 1, 2, and 3, and mercaptopurine PO on days 1-84. Cycles with imatinib mesylate and mercaptopurine repeat every 84 days for up to 104 weeks from the start of Induction IA in the absence of disease progression or unexpected toxicity.

ARM B (SR PATIENTS ASSIGNED TO ARM B):

INTERIM MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-63, vincristine sulfate IV over 1 minute and high dose methotrexate IV over 24 hours on days 1, 15, 29, and 43, leucovorin calcium or levoleucovorin PO or IV on days 3-4, 17-18, 31-32, and 45-46, mercaptopurine PO on days 1-56, and methotrexate IT on days 1 and 29 in the absence of disease progression or unexpected toxicity.

DELAYED INTENSIFICATION PART 1: Patients receive imatinib mesylate PO QD or BID on days 1-28, methotrexate IT on day 1, dexamethasone PO BID or IV on days 1-7 and 15-21, vincristine sulfate IV over 1 minute, dexrazoxane hydrochloride IV over 15 minutes, and doxorubicin IV over 3-15 minutes on days 1, 8, and 15, and pegaspargase or calaspargase pegol IV over 1-2 hours or IM on day 4 in the absence of disease progression or unexpected toxicity.

DELAYED INTENSIFICATION PART 2: Patients receive imatinib mesylate PO QD on days 29-56, cyclophosphamide IV over 30-60 minutes on day 29, thioguanine PO on days 29-42, cytarabine IV over 1-30 minutes or SC on days 29-32 and 36-39, methotrexate IT on days 29 and 36, vincristine sulfate IV over 1 minute on days 43 and 50, and pegaspargase or calaspargase pegol IV over 1-2 hours on day 43 in the absence of disease progression or unexpected toxicity.

INTERIM MAINTENANCE WITH CAPIZZI METHOTREXATE: Patients receive imatinib mesylate PO QD or BID on days 1-56, vincristine sulfate IV over 1 minute and methotrexate IV over 2-15 minutes on days 1, 11, 21, 31, and 41, methotrexate IT on days 1 and 31, and pegaspargase or calaspargase pegol IV over 1-2 hours on days 2 and 23 in the absence of disease progression or unexpected toxicity.

MAINTENANCE: Patients receive imatinib mesylate PO QD or BID on days 1-84, vincristine sulfate IV over 1 minute on days 1, 29, and 57, prednisolone PO BID (or methylprednisolone IV for cycle 1 and 2) on days 1-5, 29-33, and 57-61, mercaptopurine PO on days 1-84, methotrexate PO QW, and methotrexate IT on day 1 (and day 29 for cycle 1 and 2). Cycles repeat every 84 days for up to 104 weeks from the start of Induction IA in the absence of disease progression or unexpected toxicity.

ARM C (HR PATIENTS):

CONSOLIDATION BLOCK 1: Patients receive imatinib mesylate, methotrexate, cytarabine, therapeutic hydrocortisone, high dose methotrexate, vincristine sulfate, dexamethasone, leucovorin calcium or levoleucovorin, high dose cytarabine, and pegaspargase or calaspargase pegol as in Arm A Consolidation Block 1, and filgrastim SC or IV on day 7 in the absence of disease progression or unexpected toxicity.

CONSOLIDATION BLOCK 2: Patients receive imatinib mesylate, methotrexate, cytarabine, therapeutic hydrocortisone, high dose methotrexate, dexamethasone, vincristine sulfate, ifosfamide, leucovorin calcium or levoleucovorin, dexrazoxane hydrochloride, daunorubicin hydrochloride, pegaspargase or calaspargase pegol, and filgrastim as Arm A Consolidation Block 2 in the absence of disease progression or unexpected toxicity.

CONSOLIDATION BLOCK 3: Patients receive imatinib mesylate, dexamethasone, etoposide, methotrexate, cytarabine, therapeutic hydrocortisone, pegaspargase or calaspargase pegol, and filgrastim as in Arm A Consolidation Block 3, and high dose cytarabine IV over 3 hours on days 1-2 in the absence of disease progression or unexpected toxicity.

HSCT: Patients undergo HSCT on day 0. Patients who do not proceed to HSCT receive Delayed Intensification 1, Interim Maintenance, Delayed Intensification 2, and Maintenance as in Arm A.

POST-HSCT: Patients receive imatinib mesylate PO QD or BID starting on days 56-365 in the in the absence of disease progression or unexpected toxicity.

After completion of study treatment, patients are followed up every year for 3 years.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

352

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

      • Riyadh, Arabia Saudyjska, 11211
        • King Faisal Specialist Hospital and Research Centre
    • New South Wales
      • Hunter Regional Mail Centre, New South Wales, Australia, 2310
        • John Hunter Children's Hospital
      • Randwick, New South Wales, Australia, 2031
        • Sydney Children's Hospital
      • Westmead, New South Wales, Australia, 2145
        • The Children's Hospital at Westmead
    • Queensland
      • South Brisbane, Queensland, Australia, 4101
        • Queensland Children's Hospital
    • Western Australia
      • Perth, Western Australia, Australia, 6008
        • Princess Margaret Hospital for Children
      • Perth, Western Australia, Australia, 6009
        • Perth Children's Hospital
      • Vienna, Austria, 1090
        • St. Anna Children's Hospital
    • Flemish Brabant
      • Leuven, Flemish Brabant, Belgia, 3000
        • Hospitals Leuven
      • Santiago, Chile
        • Hospital Roberto del Rio-Universidad de Chile
      • Prague, Czechy, 15018, 5-Motol
        • University Hospital Motol
      • Tampere, Finlandia, 33521
        • Tampere University Hospital
      • Rennes, Francja, 35203
        • CHU Hopital Sud
      • Utrecht, Holandia, 3584 CT
        • Princess Máxima Center for Pediatric Oncology
    • Kowloon
      • Kowloon Bay, Kowloon, Hongkong
        • Hong Kong Children's Hospital
    • Central District
      • Petah Tikva, Central District, Izrael, 4920235
        • Schneider Children's Medical Center of Israel
      • Québec, Kanada, G1V 4G2
        • CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
    • Alberta
      • Calgary, Alberta, Kanada, T3B 6A8
        • Alberta Children's Hospital
      • Edmonton, Alberta, Kanada, T6G 2B7
        • University of Alberta Hospital
    • British Columbia
      • Vancouver, British Columbia, Kanada, V6H 3V4
        • British Columbia Children's Hospital
    • Manitoba
      • Winnipeg, Manitoba, Kanada, R3E 0V9
        • CancerCare Manitoba
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3K 6R8
        • IWK Health Centre
    • Ontario
      • Hamilton, Ontario, Kanada, L8N 3Z5
        • McMaster Children's Hospital at Hamilton Health Sciences
      • Kingston, Ontario, Kanada, K7L 2V7
        • Kingston Health Sciences Centre
      • London, Ontario, Kanada, N6A 5W9
        • Children's Hospital
      • Ottawa, Ontario, Kanada, K1H 8L1
        • Children's Hospital of Eastern Ontario
      • Toronto, Ontario, Kanada, M5G 1X8
        • Hospital for Sick Children
    • Quebec
      • Montreal, Quebec, Kanada, H3H 1P3
        • The Montreal Children's Hospital of the MUHC
      • Montreal, Quebec, Kanada, H3T 1C5
        • Centre Hospitalier Universitaire Sainte-Justine
      • Sherbrooke, Quebec, Kanada, J1H 5N4
        • Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
    • Saskatchewan
      • Saskatoon, Saskatchewan, Kanada, S7N 4H4
        • Saskatoon Cancer Centre
      • Saskatoon, Saskatchewan, Kanada, S7N 0W8
        • Jim Pattison Children's Hospital
      • Hamburg, Niemcy, 20246
        • Universitätsklinik Eppendorf
    • Schleswig-Holstein
      • Kiel, Schleswig-Holstein, Niemcy, 24105
        • University Medical Center chleswig- Campus Kiel
      • Christchurch, Nowa Zelandia, 8011
        • Christchurch Hospital
    • Auckland
      • Grafton, Auckland, Nowa Zelandia, 1145
        • Starship Children's Hospital
      • Caguas, Portoryko, 00726
        • HIMA San Pablo Oncologic Hospital
      • San Juan, Portoryko, 00926
        • University Pediatric Hospital
      • San Juan, Portoryko, 00912
        • San Jorge Children's Hospital
    • Alabama
      • Birmingham, Alabama, Stany Zjednoczone, 35233
        • Children's Hospital of Alabama
      • Mobile, Alabama, Stany Zjednoczone, 36604
        • USA Health Strada Patient Care Center
    • Alaska
      • Anchorage, Alaska, Stany Zjednoczone, 99508
        • Providence Alaska Medical Center
    • Arizona
      • Mesa, Arizona, Stany Zjednoczone, 85202
        • Banner Children's at Desert
      • Phoenix, Arizona, Stany Zjednoczone, 85016
        • Phoenix Childrens Hospital
      • Tucson, Arizona, Stany Zjednoczone, 85719
        • Banner University Medical Center - Tucson
    • Arkansas
      • Little Rock, Arkansas, Stany Zjednoczone, 72202-3591
        • Arkansas Children's Hospital
    • California
      • Downey, California, Stany Zjednoczone, 90242
        • Kaiser Permanente Downey Medical Center
      • Duarte, California, Stany Zjednoczone, 91010
        • City of Hope Comprehensive Cancer Center
      • Loma Linda, California, Stany Zjednoczone, 92354
        • Loma Linda University Medical Center
      • Long Beach, California, Stany Zjednoczone, 90806
        • Miller Children's and Women's Hospital Long Beach
      • Los Angeles, California, Stany Zjednoczone, 90048
        • Cedars-Sinai Medical Center
      • Los Angeles, California, Stany Zjednoczone, 90027
        • Children's Hospital Los Angeles
      • Madera, California, Stany Zjednoczone, 93636
        • Valley Children's Hospital
      • Oakland, California, Stany Zjednoczone, 94609
        • UCSF Benioff Children's Hospital Oakland
      • Oakland, California, Stany Zjednoczone, 94611
        • Kaiser Permanente-Oakland
      • Orange, California, Stany Zjednoczone, 92868
        • Children's Hospital of Orange County
      • Palo Alto, California, Stany Zjednoczone, 94304
        • Lucile Packard Children's Hospital Stanford University
      • Sacramento, California, Stany Zjednoczone, 95817
        • University of California Davis Comprehensive Cancer Center
      • San Diego, California, Stany Zjednoczone, 92123
        • Rady Children's Hospital - San Diego
      • San Francisco, California, Stany Zjednoczone, 94158
        • UCSF Medical Center-Mission Bay
    • Colorado
      • Aurora, Colorado, Stany Zjednoczone, 80045
        • Children's Hospital Colorado
      • Denver, Colorado, Stany Zjednoczone, 80218
        • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
    • Connecticut
      • Hartford, Connecticut, Stany Zjednoczone, 06106
        • Connecticut Children's Medical Center
      • New Haven, Connecticut, Stany Zjednoczone, 06520
        • Yale University
    • Delaware
      • Wilmington, Delaware, Stany Zjednoczone, 19803
        • Alfred I duPont Hospital for Children
    • District of Columbia
      • Washington D.C., District of Columbia, Stany Zjednoczone, 20010
        • Children's National Medical Center
      • Washington D.C., District of Columbia, Stany Zjednoczone, 20007
        • MedStar Georgetown University Hospital
    • Florida
      • Fort Lauderdale, Florida, Stany Zjednoczone, 33316
        • Broward Health Medical Center
      • Fort Myers, Florida, Stany Zjednoczone, 33908
        • Golisano Children's Hospital of Southwest Florida
      • Gainesville, Florida, Stany Zjednoczone, 32610
        • UF Health Cancer Institute - Gainesville
      • Hollywood, Florida, Stany Zjednoczone, 33021
        • Memorial Regional Hospital/Joe DiMaggio Children's Hospital
      • Jacksonville, Florida, Stany Zjednoczone, 32207
        • Nemours Children's Clinic-Jacksonville
      • Loxahatchee Groves, Florida, Stany Zjednoczone, 33470
        • Palms West Radiation Therapy
      • Miami, Florida, Stany Zjednoczone, 33155
        • Nicklaus Children's Hospital
      • Miami, Florida, Stany Zjednoczone, 33136
        • University of Miami Miller School of Medicine-Sylvester Cancer Center
      • Miami, Florida, Stany Zjednoczone, 33176
        • Miami Cancer Institute
      • Orlando, Florida, Stany Zjednoczone, 32827
        • Nemours Children's Hospital
      • Orlando, Florida, Stany Zjednoczone, 32803
        • AdventHealth Orlando
      • Orlando, Florida, Stany Zjednoczone, 32806
        • Arnold Palmer Hospital for Children
      • Pensacola, Florida, Stany Zjednoczone, 32504
        • Sacred Heart Hospital
      • St. Petersburg, Florida, Stany Zjednoczone, 33701
        • Johns Hopkins All Children's Hospital
      • Tampa, Florida, Stany Zjednoczone, 33606
        • Tampa General Hospital
      • Tampa, Florida, Stany Zjednoczone, 33607
        • Saint Joseph's Hospital/Children's Hospital-Tampa
      • West Palm Beach, Florida, Stany Zjednoczone, 33407
        • Saint Mary's Medical Center
    • Georgia
      • Atlanta, Georgia, Stany Zjednoczone, 30329
        • Children's Healthcare of Atlanta - Arthur M Blank Hospital
      • Augusta, Georgia, Stany Zjednoczone, 30912
        • Augusta University Medical Center
      • Macon, Georgia, Stany Zjednoczone, 31201
        • Atrium Health Navicent
      • Savannah, Georgia, Stany Zjednoczone, 31404
        • Memorial Health University Medical Center
    • Hawaii
      • Honolulu, Hawaii, Stany Zjednoczone, 96826
        • Kapiolani Medical Center for Women and Children
    • Idaho
      • Boise, Idaho, Stany Zjednoczone, 83712
        • Saint Luke's Cancer Institute - Boise
    • Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60637
        • University of Chicago Comprehensive Cancer Center
      • Chicago, Illinois, Stany Zjednoczone, 60612
        • University of Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60611
        • Lurie Children's Hospital-Chicago
      • Oak Lawn, Illinois, Stany Zjednoczone, 60453
        • Advocate Children's Hospital-Oak Lawn
      • Park Ridge, Illinois, Stany Zjednoczone, 60068
        • Advocate Children's Hospital-Park Ridge
      • Peoria, Illinois, Stany Zjednoczone, 61637
        • OSF Children's Hospital of Illinois
      • Springfield, Illinois, Stany Zjednoczone, 62702
        • Southern Illinois University School of Medicine
    • Indiana
      • Indianapolis, Indiana, Stany Zjednoczone, 46202
        • Riley Hospital for Children
      • Indianapolis, Indiana, Stany Zjednoczone, 46260
        • Ascension Saint Vincent Indianapolis Hospital
    • Iowa
      • Des Moines, Iowa, Stany Zjednoczone, 50309
        • Blank Children's Hospital
      • Iowa City, Iowa, Stany Zjednoczone, 52242
        • University of Iowa/Holden Comprehensive Cancer Center
    • Kentucky
      • Lexington, Kentucky, Stany Zjednoczone, 40536
        • University of Kentucky/Markey Cancer Center
      • Louisville, Kentucky, Stany Zjednoczone, 40202
        • Norton Children's Hospital
    • Louisiana
      • New Orleans, Louisiana, Stany Zjednoczone, 70121
        • Ochsner Medical Center Jefferson
    • Maine
      • Bangor, Maine, Stany Zjednoczone, 04401
        • Eastern Maine Medical Center
      • Scarborough, Maine, Stany Zjednoczone, 04074
        • Maine Children's Cancer Program
    • Maryland
      • Baltimore, Maryland, Stany Zjednoczone, 21287
        • Johns Hopkins University/Sidney Kimmel Cancer Center
      • Baltimore, Maryland, Stany Zjednoczone, 21215
        • Sinai Hospital of Baltimore
      • Bethesda, Maryland, Stany Zjednoczone, 20889-5600
        • Walter Reed National Military Medical Center
    • Massachusetts
      • Boston, Massachusetts, Stany Zjednoczone, 02215
        • Dana-Farber Cancer Institute
      • Boston, Massachusetts, Stany Zjednoczone, 02114
        • Massachusetts General Hospital Cancer Center
      • Boston, Massachusetts, Stany Zjednoczone, 02111
        • Tufts Children's Hospital
      • Worcester, Massachusetts, Stany Zjednoczone, 01655
        • UMass Memorial Medical Center - University Campus
    • Michigan
      • Ann Arbor, Michigan, Stany Zjednoczone, 48109
        • C S Mott Children's Hospital
      • Detroit, Michigan, Stany Zjednoczone, 48201
        • Children's Hospital of Michigan
      • Detroit, Michigan, Stany Zjednoczone, 48236
        • Henry Ford Health Saint John Hospital
      • East Lansing, Michigan, Stany Zjednoczone, 48823
        • Michigan State University
      • Grand Rapids, Michigan, Stany Zjednoczone, 49503
        • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
      • Kalamazoo, Michigan, Stany Zjednoczone, 49007
        • Bronson Methodist Hospital
      • Royal Oak, Michigan, Stany Zjednoczone, 48073
        • Corewell Health Children's
    • Minnesota
      • Minneapolis, Minnesota, Stany Zjednoczone, 55404
        • Children's Hospitals and Clinics of Minnesota - Minneapolis
      • Minneapolis, Minnesota, Stany Zjednoczone, 55455
        • University of Minnesota/Masonic Cancer Center
    • Mississippi
      • Jackson, Mississippi, Stany Zjednoczone, 39216
        • University of Mississippi Medical Center
    • Missouri
      • Columbia, Missouri, Stany Zjednoczone, 65212
        • University of Missouri Children's Hospital
      • Kansas City, Missouri, Stany Zjednoczone, 64108
        • Children's Mercy Hospitals and Clinics
      • St Louis, Missouri, Stany Zjednoczone, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Stany Zjednoczone, 63141
        • Mercy Hospital Saint Louis
    • Nebraska
      • Omaha, Nebraska, Stany Zjednoczone, 68198
        • University of Nebraska Medical Center
      • Omaha, Nebraska, Stany Zjednoczone, 68114
        • Children's Hospital and Medical Center of Omaha
    • Nevada
      • Las Vegas, Nevada, Stany Zjednoczone, 89144
        • Summerlin Hospital Medical Center
      • Las Vegas, Nevada, Stany Zjednoczone, 89109
        • Sunrise Hospital and Medical Center
      • Las Vegas, Nevada, Stany Zjednoczone, 89135
        • Alliance for Childhood Diseases/Cure 4 the Kids Foundation
      • Las Vegas, Nevada, Stany Zjednoczone, 89102
        • University Medical Center of Southern Nevada
      • Reno, Nevada, Stany Zjednoczone, 89502
        • Renown Regional Medical Center
    • New Hampshire
      • Lebanon, New Hampshire, Stany Zjednoczone, 03756
        • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
    • New Jersey
      • Hackensack, New Jersey, Stany Zjednoczone, 07601
        • Hackensack University Medical Center
      • Morristown, New Jersey, Stany Zjednoczone, 07960
        • Morristown Medical Center
      • Neptune City, New Jersey, Stany Zjednoczone, 07753
        • Jersey Shore Medical Center
      • New Brunswick, New Jersey, Stany Zjednoczone, 08901
        • Saint Peter's University Hospital
      • New Brunswick, New Jersey, Stany Zjednoczone, 08903
        • Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
      • Newark, New Jersey, Stany Zjednoczone, 07112
        • Newark Beth Israel Medical Center
      • Paterson, New Jersey, Stany Zjednoczone, 07503
        • Saint Joseph's Regional Medical Center
    • New Mexico
      • Albuquerque, New Mexico, Stany Zjednoczone, 87106
        • Presbyterian Hospital
      • Albuquerque, New Mexico, Stany Zjednoczone, 87106
        • University of New Mexico Cancer Center
    • New York
      • Albany, New York, Stany Zjednoczone, 12208
        • Albany Medical Center
      • Brooklyn, New York, Stany Zjednoczone, 11219
        • Maimonides Medical Center
      • Buffalo, New York, Stany Zjednoczone, 14263
        • Roswell Park Cancer Institute
      • Mineola, New York, Stany Zjednoczone, 11501
        • NYU Langone Hospital - Long Island
      • New Hyde Park, New York, Stany Zjednoczone, 11040
        • The Steven and Alexandra Cohen Children's Medical Center of New York
      • New York, New York, Stany Zjednoczone, 10065
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, Stany Zjednoczone, 10029
        • Mount Sinai Hospital
      • New York, New York, Stany Zjednoczone, 10032
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
      • New York, New York, Stany Zjednoczone, 10016
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
      • Rochester, New York, Stany Zjednoczone, 14642
        • University of Rochester
      • Stony Brook, New York, Stany Zjednoczone, 11794
        • Stony Brook University Medical Center
      • Syracuse, New York, Stany Zjednoczone, 13210
        • State University of New York Upstate Medical University
      • The Bronx, New York, Stany Zjednoczone, 10467
        • Montefiore Medical Center - Moses Campus
      • Valhalla, New York, Stany Zjednoczone, 10595
        • New York Medical College
    • North Carolina
      • Asheville, North Carolina, Stany Zjednoczone, 28801
        • Mission Hospital
      • Chapel Hill, North Carolina, Stany Zjednoczone, 27599
        • UNC Lineberger Comprehensive Cancer Center
      • Charlotte, North Carolina, Stany Zjednoczone, 28203
        • Carolinas Medical Center/Levine Cancer Institute
      • Charlotte, North Carolina, Stany Zjednoczone, 28204
        • Novant Health Presbyterian Medical Center
      • Durham, North Carolina, Stany Zjednoczone, 27710
        • Duke University Medical Center
      • Greenville, North Carolina, Stany Zjednoczone, 27834
        • East Carolina University
      • Winston-Salem, North Carolina, Stany Zjednoczone, 27157
        • Wake Forest University Health Sciences
    • North Dakota
      • Fargo, North Dakota, Stany Zjednoczone, 58122
        • Sanford Broadway Medical Center
    • Ohio
      • Akron, Ohio, Stany Zjednoczone, 44308
        • Children's Hospital Medical Center of Akron
      • Cincinnati, Ohio, Stany Zjednoczone, 45229
        • Cincinnati Children's Hospital Medical Center
      • Cleveland, Ohio, Stany Zjednoczone, 44195
        • Cleveland Clinic Foundation
      • Cleveland, Ohio, Stany Zjednoczone, 44106
        • Rainbow Babies and Childrens Hospital
      • Columbus, Ohio, Stany Zjednoczone, 43205
        • Nationwide Children's Hospital
      • Dayton, Ohio, Stany Zjednoczone, 45404
        • Dayton Children's Hospital
      • Toledo, Ohio, Stany Zjednoczone, 43606
        • ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
    • Oklahoma
      • Oklahoma City, Oklahoma, Stany Zjednoczone, 73104
        • University of Oklahoma Health Sciences Center
    • Oregon
      • Portland, Oregon, Stany Zjednoczone, 97239
        • Oregon Health and Science University
      • Portland, Oregon, Stany Zjednoczone, 97227
        • Legacy Emanuel Children's Hospital
    • Pennsylvania
      • Allentown, Pennsylvania, Stany Zjednoczone, 18103
        • Lehigh Valley Hospital-Cedar Crest
      • Danville, Pennsylvania, Stany Zjednoczone, 17822
        • Geisinger Medical Center
      • Hershey, Pennsylvania, Stany Zjednoczone, 17033
        • Penn State Children's Hospital
      • Philadelphia, Pennsylvania, Stany Zjednoczone, 19104
        • Children's Hospital of Philadelphia
      • Philadelphia, Pennsylvania, Stany Zjednoczone, 19134
        • Saint Christopher's Hospital for Children
      • Pittsburgh, Pennsylvania, Stany Zjednoczone, 15224
        • Children's Hospital of Pittsburgh of UPMC
    • Rhode Island
      • Providence, Rhode Island, Stany Zjednoczone, 02903
        • Rhode Island Hospital
    • South Carolina
      • Charleston, South Carolina, Stany Zjednoczone, 29425
        • Medical University of South Carolina
      • Columbia, South Carolina, Stany Zjednoczone, 29203
        • Prisma Health Richland Hospital
      • Greenville, South Carolina, Stany Zjednoczone, 29605
        • BI-LO Charities Children's Cancer Center
    • South Dakota
      • Sioux Falls, South Dakota, Stany Zjednoczone, 57117-5134
        • Sanford USD Medical Center - Sioux Falls
    • Tennessee
      • Chattanooga, Tennessee, Stany Zjednoczone, 37403
        • T C Thompson Children's Hospital
      • Knoxville, Tennessee, Stany Zjednoczone, 37916
        • East Tennessee Childrens Hospital
      • Nashville, Tennessee, Stany Zjednoczone, 37232
        • Vanderbilt University/Ingram Cancer Center
      • Nashville, Tennessee, Stany Zjednoczone, 37203
        • The Children's Hospital at TriStar Centennial
    • Texas
      • Amarillo, Texas, Stany Zjednoczone, 79106
        • Texas Tech University Health Sciences Center-Amarillo
      • Austin, Texas, Stany Zjednoczone, 78723
        • Dell Children's Medical Center of Central Texas
      • Corpus Christi, Texas, Stany Zjednoczone, 78411
        • Driscoll Children's Hospital
      • Dallas, Texas, Stany Zjednoczone, 75390
        • UT Southwestern/Simmons Cancer Center-Dallas
      • Dallas, Texas, Stany Zjednoczone, 75230
        • Medical City Dallas Hospital
      • El Paso, Texas, Stany Zjednoczone, 79905
        • El Paso Children's Hospital
      • Fort Worth, Texas, Stany Zjednoczone, 76104
        • Cook Children's Medical Center
      • Houston, Texas, Stany Zjednoczone, 77030
        • UT MD Anderson Cancer Center
      • Houston, Texas, Stany Zjednoczone, 77030
        • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
      • Lubbock, Texas, Stany Zjednoczone, 79410
        • Covenant Children's Hospital
      • Lubbock, Texas, Stany Zjednoczone, 79415
        • UMC Cancer Center / UMC Health System
      • San Antonio, Texas, Stany Zjednoczone, 78207
        • Children's Hospital of San Antonio
      • San Antonio, Texas, Stany Zjednoczone, 78229
        • Methodist Children's Hospital of South Texas
      • Temple, Texas, Stany Zjednoczone, 76508
        • Scott and White Memorial Hospital
    • Utah
      • Salt Lake City, Utah, Stany Zjednoczone, 84113
        • Primary Children's Hospital
    • Vermont
      • Burlington, Vermont, Stany Zjednoczone, 05405
        • University of Vermont and State Agricultural College
    • Virginia
      • Charlottesville, Virginia, Stany Zjednoczone, 22908
        • University of Virginia Cancer Center
      • Falls Church, Virginia, Stany Zjednoczone, 22042
        • Inova Fairfax Hospital
      • Norfolk, Virginia, Stany Zjednoczone, 23507
        • Children's Hospital of The King's Daughters
      • Portsmouth, Virginia, Stany Zjednoczone, 23708-2197
        • Naval Medical Center - Portsmouth
      • Richmond, Virginia, Stany Zjednoczone, 23298
        • VCU Massey Comprehensive Cancer Center
      • Roanoke, Virginia, Stany Zjednoczone, 24014
        • Carilion Children's
    • Washington
      • Seattle, Washington, Stany Zjednoczone, 98105
        • Seattle Children's Hospital
      • Spokane, Washington, Stany Zjednoczone, 99204
        • Providence Sacred Heart Medical Center and Children's Hospital
      • Tacoma, Washington, Stany Zjednoczone, 98405
        • Mary Bridge Children's Hospital and Health Center
      • Tacoma, Washington, Stany Zjednoczone, 98431
        • Madigan Army Medical Center
    • West Virginia
      • Huntington, West Virginia, Stany Zjednoczone, 25701
        • Edwards Comprehensive Cancer Center
      • Morgantown, West Virginia, Stany Zjednoczone, 26506
        • West Virginia University Healthcare
    • Wisconsin
      • Green Bay, Wisconsin, Stany Zjednoczone, 54301
        • Saint Vincent Hospital Cancer Center Green Bay
      • Madison, Wisconsin, Stany Zjednoczone, 53792
        • University of Wisconsin Carbone Cancer Center - University Hospital
      • Marshfield, Wisconsin, Stany Zjednoczone, 54449
        • Marshfield Medical Center-Marshfield
      • Milwaukee, Wisconsin, Stany Zjednoczone, 53226
        • Children's Hospital of Wisconsin
      • Zurich, Szwajcaria, CH8032
        • University Children's Hospital
    • Skåne County
      • Lund, Skåne County, Szwecja, 22185
        • Skane University Hospital
      • Monza, Włochy, 20900
        • Clinica Pediatrica Università Milano-Bicocca Ospedale S. Gerardo/Fondazione MBBM

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

1 rok do 21 lat (Dziecko, Dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • For patients enrolled on APEC14B1 prior to enrollment on AALL1631, the required diagnostic bone marrow sample has been fulfilled

    • For patients who have not previously enrolled on APEC14B1 prior to enrollment on AALL1631, a baseline diagnostic sample (or peripheral blood sample with blasts if marrow sample unavailable) must be available to develop an MRD probe
    • In addition, laboratory reports detailing evidence of BCR::ABL1 fusion or ABL-class fusion must be submitted for rapid central review within 72 hours of study enrollment
  • >= 1 year (365 days) and =< 21 years at ALL diagnosis

  • Ph+ (BCR::ABL1 fusion): newly diagnosed de novo ALL (B-ALL or T-ALL) or mixed phenotypic acute leukemia (MPAL meeting 2016 World Health Organization [WHO] definition) with definitive evidence of BCR::ABL1 fusion by karyotype, fluorescence in situ hybridization (FISH) and/or molecular methodologies

  • ABL-class fusion: newly diagnosed B-ALL with definitive evidence of ABL-class fusions. ABL-class fusions are defined as those involving the following genes: ABL1, ABL2, CSF1R, PDGFRB, PDGFRA. Methods of detection include fluorescence in-situ hybridization ([FISH], e.g. using break-apart or colocalization signals probes), multiplex or singleplex reverse-transcription polymerase chain reaction (RT-PCR), whole transcriptome or panel-based RNA-sequencing (e.g. TruSight RNA Pan-Cancer Panel; Illumina, San Diego, California [CA], United States of America [USA] or similar)

  • Ph+ patients must have previously started Induction therapy, which includes vincristine, a corticosteroid, pegaspargase, with or without anthracycline, and/or other standard cytotoxic chemotherapy

  • Ph+ patients have not received more than 14 days of multiagent Induction therapy beginning with the first dose of vinCRIStine

  • Ph+ patients may have started imatinib prior to study entry but have not received more than 14 days of imatinib

  • ABL-class fusion patients must have previously completed the 4 or 5 weeks of multiagent Induction chemotherapy (Induction IA phase)

  • ABL-class fusion patients may have started imatinib during Induction IA, at the same time of or after the first vinCRIStine dose

  • Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2

  • Direct bilirubin =< 2.0 mg/dL

  • Shortening fraction of >= 27% by echocardiogram

  • Ejection fraction of >= 50% by radionuclide angiogram or echocardiogram

  • Corrected QT interval, QTc < 480 msec

    • Note: Repeat echocardiogram and electrocardiogram are not required if they were performed at or after initial ALL diagnosis, before study enrollment
  • Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or serum creatinine within normal limits based on age/gender, as follows:

    • 1 to < 2 years: maximum serum creatinine 0.6 mg/dL (both male and female)
    • 2 to < 6 years: maximum serum creatinine 0.8 mg/dL (both male and female)
    • 6 to < 10 years: maximum serum creatinine 1 mg/dL (both male and female)
    • 10 to < 13 years: maximum serum creatinine 1.2 mg/dL (both male and female)
    • 13 to < 16 years: maximum serum creatinine 1.5 mg/dL (male), 1.4 mg/dL (female)
    • >= 16 years: maximum serum creatinine 1.7 mg/dL (male), 1.4 mg/dL (female)

Exclusion Criteria:

  • Known history of chronic myelogenous leukemia (CML)

  • ALL developing after a previous cancer treated with cytotoxic chemotherapy

  • Active, uncontrolled infection, or active systemic illness that requires ongoing vasopressor support or mechanical ventilation

  • Down syndrome

  • Pregnancy and breast feeding

    • Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential
    • Lactating females who plan to breastfeed their infants
    • Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of treatment according to protocol
  • Patients with congenital long QT syndrome, history of ventricular arrhythmias or heart block

  • Prior treatment with dasatinib, or any TKI other than imatinib

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Arm A (imatinib mesylate, EsPhALL chemotherapy)

See Detailed Description

Correlative studies

Given IV

Inne nazwy:
  • Cytoksan
  • CTX
  • (-)-cyklofosfamid
  • 2H-1,3,2-Oksazafosforyna, 2-[bis(2-chloroetylo)amino]tetrahydro-, 2-tlenek, monohydrat
  • Karloksan
  • Cyklofosfamida
  • Cyklofosfamid
  • Cykloksal
  • Clafen
  • Klafen
  • Monohydrat CP
  • Ogniwo CYCLO
  • Cykloblastyna
  • Cyklofosfam
  • Monohydrat cyklofosfamidu
  • Cyklofosfan
  • Cyklostyna
  • Cytofosfan
  • Fosfaseron
  • Genoksal
  • Genuxal
  • Ledoksyna
  • Mitoksan
  • Neosar
  • Revimmune
  • Syklofosfamid
  • WR-138719
  • Asta B 518
  • B-518
  • B518
  • WR 138719
  • WR138719
  • Frindovyx

Given IV

Inne nazwy:
  • Adriablastyna
  • Hydroksydaunomycyna
  • Hydroksylowa daunorubicyna
  • Hydroksyldaunorubicyna

Given IV

Inne nazwy:
  • Oncovin
  • Kyocristine
  • Siarczan Leurokrystyny
  • Leurokrystyna, siarczan
  • Vincasar
  • Vincosid
  • Vincrex
  • Winkrystyna, siarczan

Ancillary studies

Given IV

Inne nazwy:
  • Cerubidyna
  • Cloridrato de Daunorubicina
  • Daunoblastyna
  • Daunoblastina
  • Chlorowodorek daunomycyny
  • Daunomycyna, chlorowodorek
  • Chlorowodorek daunorubicyny
  • Daunorubicini Hydrochloridum
  • FI-6339
  • Ondena
  • RP-13057
  • Chlorowodorek rubidomycyny
  • Rubilem

Given IV

Inne nazwy:
  • Demetylo Epipodofilotoksyna Glukozyd etylidyny
  • EPEG
  • Ostatnie
  • Toposar
  • Vepesid
  • WP 16
  • VP 16-213
  • VP-16
  • VP-16-213
  • VP16
  • VP 16213
  • VP-16213
  • VP16213

Given PO

Inne nazwy:
  • 6-MP
  • Purynetol
  • 3H-Puryn-6-tiol
  • 6 MP
  • 6 Tiohipoksantyna
  • 6 Tiopuryna
  • 6-Merkaptopuryna
  • Monohydrat 6-merkaptopuryny
  • 6-purinetiol
  • 6-Tiopuryna
  • 6-tioksopuryna
  • 6H-Puryn-6-tion, 1,7-dihydro- (9CI)
  • 7-merkapto-1,3,4,6-tetrazainden
  • Alti-merkaptopuryna
  • Azatiopuryna
  • Bw 57-323H
  • Flocofil
  • Ismipur
  • Leukeryna
  • Leupuryna
  • Mercaleukim
  • Mercaleukin
  • Mercaptina
  • Merkaptopuryna
  • Merkapuryna
  • Mern
  • NCI-C04886
  • Puri-Nethol
  • Purymetol
  • Puryna, 6-merkapto-
  • Puryno-6-tiol (8CI)
  • Puryno-6-tiol, monohydrat
  • Purynotiol
  • U-4748
  • WR-2785

Given IV

Inne nazwy:
  • Medrol
  • Wyacort
  • Adlone
  • Caberdelta M
  • DepMedalone
  • Depo Moderin
  • Depo-Nisolon
  • Duralone
  • Emmetipi
  • Esameton
  • Firmacort
  • Medlone 21
  • Średnia
  • Medrol Veriderm
  • Medron
  • Mega-Gwiazda
  • Meprolon
  • Metyloprednizolon
  • Rozpuszczalny metylobetazon
  • Metrokort
  • Metyppresol
  • Metysolon
  • Predni-M-Tablin
  • Prednilen
  • Radiem
  • Sieropresol
  • Solpredon
  • Summicort
  • Urbason
  • Veriderm Medrol

Given IV

Inne nazwy:
  • Asta Z 4942
  • Asta Z-4942
  • Cyfos
  • Holoksan
  • Ifex
  • IFO
  • Komórka IFO
  • Ifolem
  • Ifomida
  • Ifomid
  • Ifosfamid
  • Ifoksan
  • IFX
  • Izo-endoksan
  • Izoendoksan
  • Izofosfamid
  • Mitoksana
  • MJF 9325
  • MJF-9325
  • Naksamid
  • Seromida
  • Tronoxal
  • Z 4942
  • Z-4942

Given IV

Inne nazwy:
  • Asparaginaza (Escherichia coli Isoenzyme II), Koniugat z alfa-(((2,5-diokso-1-pirolidynylo)oksy)karbonylo)-omega-metoksypoli(oksy-1,2-etanodiylem)
  • Szparagi
  • EZN-2285
  • SC-PEG E. Coli L-asparaginaza
  • Węglan sukcynimidylu Glikol monometoksypolietylenowy E. coli L-asparaginaza
  • Calaspargase Pegol-mknl

Given PO or IV

Inne nazwy:
  • Wellcovorin
  • kwas folinowy
  • Adinepar
  • Kalcyfolina
  • Wapń (6S)-folinian
  • Folinian wapnia
  • Leukoworyna wapnia
  • Calfolex
  • Kalinat
  • Cehafolin
  • Citofolina
  • Citrec
  • Czynnik Citrovorum
  • Cromatonbic Folinico
  • Dalisol
  • Dezintoksykacja
  • Divical
  • Ecofol
  • Emovis
  • Czynnik, Citrovorum
  • Flynoken A
  • Folaren
  • Folaksyna
  • Komórka FOLI
  • Foliben
  • Folidan
  • Folidar
  • Folinac
  • Pentahydrat soli wapniowej kwasu foliowego
  • Folinoral
  • Folinvit
  • Foliplus
  • Folix
  • Imo
  • Lederfolat
  • Lederfolin
  • Leukozar
  • leukoworyna
  • Reskufolina
  • Reskuwolina
  • Tonofolina

Given IT

Inne nazwy:
  • Abitreksat
  • Folex
  • Mikstura
  • MTX
  • Alfa-metopteryna
  • Ametopteryna
  • Brimeksat
  • CL 14377
  • CL-14377
  • Emteksat
  • Emthexat
  • Farmitreksat
  • Fauldexato
  • Folex PFS
  • Lantarel
  • Ledertreksat
  • Lumekson
  • Maxtrex
  • Medsatreksat
  • Metex
  • Metoblastyna
  • Metotreksat LPF
  • Metotreksat Metyloaminopteryna
  • Metotreksat
  • Metrotex
  • Mexate-AQ
  • Novatrex
  • Reumatreks
  • Texate
  • Tremetex
  • Trexeron
  • Trixilem
  • WR-19039
  • Jylamvo

Given IV, SC, or IT

Inne nazwy:
  • .beta.-arabinozyd cytozyny
  • 1-β.-D-Arabinofuranozylo-4-amino-2(1H)pirymidynon
  • 1-β.-D-Arabinofuranozylocytozyna
  • 1-Beta-D-arabinofuranozylo-4-amino-2(1H)pirymidynon
  • 1-Beta-D-arabinofuranozylocytozyna
  • 1.beta.-D-Arabinofuranozylocytozyna
  • 2(1H)-pirymidynon, 4-amino-1-beta-D-arabinofuranozylo-
  • 2(1H)-pirymidynon, 4-amino-1.beta.-D-arabinofuranozylo-
  • Alexan
  • Ara-C
  • Komórka ARA
  • Arabska
  • Arabinofuranozylocytozyna
  • Arabinozylocytozyna
  • Aracytydyna
  • Aracytyna
  • Arabinozyd beta-cytozyny
  • CHX-3311
  • Cytarabina
  • Cytarbel
  • Cytosar
  • Arabinozyd cytozyny
  • Cytozyno-β-arabinozyd
  • Cytozyna-beta-arabinozyd
  • Erpalfa
  • Starasid
  • Tarabina PFS
  • U 19920
  • U-19920
  • Udicil
  • WR-28453

Given PO or IV

Inne nazwy:
  • Dekadron
  • Hemady
  • Aacydeksam
  • Adekson
  • Aknichthol Dexa
  • Alba-Dex
  • Alin
  • Alin Depot
  • Alin Oftalmico
  • Ampliderma
  • Anemul mono
  • Uszny
  • Auksylozon
  • Bajkadron
  • Baycuten
  • Baycuten N
  • Kortydeksazon
  • Cortisumman
  • Dekokort
  • Dekadrol
  • Dekadron DP
  • Dekaliks
  • Dekamet
  • Dekazon R.p.
  • Dektanl
  • Dekacort
  • Deltafluoren
  • Deronil
  • Dezametazon
  • Desameton
  • Dexa-Mamallet
  • Dexa-Rhinosan
  • Dexa-Scheroson
  • Deksa-sinus
  • Deksakortal
  • Deksakortyna
  • Dexafarma
  • Deksafluoren
  • Deksalokalny
  • Deksamekortyna
  • Deksamet
  • Deksametazon Intensol
  • Deksametazon
  • Deksamonozon
  • Deksapos
  • Dexinoralny
  • Dekson
  • Dinormon
  • Dxevo
  • Fluorodelta
  • Fortekortyna
  • Gammacorten
  • Heksadekadrol
  • Heksadrol
  • Lokalizacja-F
  • Loverine
  • Metylofluorprednizolon
  • Millicorten
  • Mymetazon
  • Orgadron
  • Spersadex
  • TaperDex
  • Wisumetazon
  • ZoDex
  • LenaDex

Given IV

Inne nazwy:
  • Kardioksan
  • Totect
  • Zinecard

Given SC or IV

Inne nazwy:
  • G-CSF
  • r-metHuG-CSF
  • Neupogen
  • Filgrastym-aafi
  • Nivestym
  • Rekombinowany metionylowy czynnik stymulujący tworzenie kolonii ludzkich granulocytów
  • rG-CSF
  • Tewagrastym
  • Filgrastim Biopodobny Filgrastim-sndz
  • Zarxio
  • Filgrastym XM02
  • Tbo-filgrastym
  • Granix
  • Nivestim
  • XM02
  • Filgrastim-sndz
  • Filgrastym Biopodobny Tbo-filgrastym
  • Filgrastym-ayow
  • Releuko
  • Neutroval

Given PO

Inne nazwy:
  • Gleevec
  • CGP 57148
  • CGP57148B
  • Glivec
  • STI 571
  • STI-571
  • STI571
  • CGP-57148B
  • CGP 57148B
  • CGP-57148
  • CGP57148
  • Imarech
  • Imat
  • Imkeldi

Given PO or IV

Inne nazwy:
  • Kwas lewofolinowy
  • Lewofolinian
  • CL-307 782
  • Elvorine, izovorin, lewofolen, levorin
  • Isovorin
  • L-leuocoworin
  • Khapzory

Given IV

Inne nazwy:
  • L-asparaginaza z glikolem polietylenowym
  • Oncaspar
  • Oncaspar IV
  • PEG-asparaginaza
  • PEG-L-asparaginaza
  • PEG-L-asparaginaza (Enzon - Kyowa Hakko)
  • PEGLA
  • L-asparaginaza glikolu polietylenowego

Given PO

Inne nazwy:
  • (11beta)-11,17,21-Trihydroksypregna-1,4-dien-3,20-dion
  • .delta.1-Hydrokortyzon
  • Adnizolon
  • Aprednislon
  • Kapsoid
  • Kortalon
  • Kortyzolon
  • Dakortyna H
  • Dekaprednil
  • Decortin H
  • Delta(1)Hydrokortyzon
  • Delta- Cortef
  • Delta-Cortef
  • Delta-Diona
  • Delta-F
  • Delta-forikol
  • Delta1-dehydrohydrokortyzon
  • Deltakortryl
  • Deltahydrokortyzon
  • Deltasolon
  • Deltidrozol
  • Dhasolon
  • Di-Adreson-F
  • Dontisolon D
  • Estilsona
  • Fisopred
  • Frisolona
  • Gupizon
  • Hostakortyna H
  • Hydeltra
  • Hydeltrazol
  • Klismacort
  • Kuhlprednon
  • Lenizolon
  • Lepi-Cortinolo
  • Linola-H N
  • Linola-H-Fett N
  • Longiprednil
  • Metakortandralon
  • Meti Derm
  • Metykortelon
  • Opredson
  • Panafkortelon
  • Prekortyzyl
  • Pred-Clysma
  • Predeltilon
  • Predni-Coelin
  • Predni-Helvacort
  • Prednikortelon
  • Prednizolon
  • Prelone
  • Prenilon
  • Sterane

Given IT

Inne nazwy:
  • Aeroseb-HC
  • Barseb HC
  • Barseb-HC
  • Cetacort
  • Cort-Dome
  • Cortef
  • Cortenema
  • Cortifan
  • Kortyzol
  • Cortispray
  • Kortril
  • Dermacort
  • Domolen
  • Eldecort
  • Hautosone
  • Heb-Cort
  • Hydrokortyzon
  • Hydrokorton
  • Hiton
  • Komed-HC
  • Nutracort
  • Proctocort
  • Prostokątny

Given PO

Inne nazwy:
  • 6-TG
  • 2-amino 6MP
  • 2-amino-1,7-dihydro-6H-puryno-6-tion
  • 2-amino-6-merkaptopuryna
  • 2-amino-6-purynotiol
  • 2-aminopuryno-6-tiol
  • 2-aminopuryno-6(1H)-tion
  • Półwodzian 2-aminopuryno-6-tiolu
  • 2-Merkapto-6-aminopuryna
  • 6-amino-2-merkaptopuryna
  • 6-Merkapto-2-aminopuryna
  • 6-Merkaptoguanina
  • 6H-Puryn-6-tion, 2-amino-1,7-dihydro- (9CI)
  • BW 5071
  • Lanvis
  • Tabletka
  • Półwodzian tioguaniny
  • Hydrat tioguaniny
  • Tioguanin
  • Tioguanina
  • Witaj U3B
  • WR-1141
  • X 27
Eksperymentalny: Arm B (imatinib mesylate, COG/BFM chemotherapy)

See Detailed Description.

Correlative studies

Given IV

Inne nazwy:
  • Cytoksan
  • CTX
  • (-)-cyklofosfamid
  • 2H-1,3,2-Oksazafosforyna, 2-[bis(2-chloroetylo)amino]tetrahydro-, 2-tlenek, monohydrat
  • Karloksan
  • Cyklofosfamida
  • Cyklofosfamid
  • Cykloksal
  • Clafen
  • Klafen
  • Monohydrat CP
  • Ogniwo CYCLO
  • Cykloblastyna
  • Cyklofosfam
  • Monohydrat cyklofosfamidu
  • Cyklofosfan
  • Cyklostyna
  • Cytofosfan
  • Fosfaseron
  • Genoksal
  • Genuxal
  • Ledoksyna
  • Mitoksan
  • Neosar
  • Revimmune
  • Syklofosfamid
  • WR-138719
  • Asta B 518
  • B-518
  • B518
  • WR 138719
  • WR138719
  • Frindovyx

Given IV

Inne nazwy:
  • Adriablastyna
  • Hydroksydaunomycyna
  • Hydroksylowa daunorubicyna
  • Hydroksyldaunorubicyna

Given IV

Inne nazwy:
  • Oncovin
  • Kyocristine
  • Siarczan Leurokrystyny
  • Leurokrystyna, siarczan
  • Vincasar
  • Vincosid
  • Vincrex
  • Winkrystyna, siarczan

Ancillary studies

Given PO

Inne nazwy:
  • 6-MP
  • Purynetol
  • 3H-Puryn-6-tiol
  • 6 MP
  • 6 Tiohipoksantyna
  • 6 Tiopuryna
  • 6-Merkaptopuryna
  • Monohydrat 6-merkaptopuryny
  • 6-purinetiol
  • 6-Tiopuryna
  • 6-tioksopuryna
  • 6H-Puryn-6-tion, 1,7-dihydro- (9CI)
  • 7-merkapto-1,3,4,6-tetrazainden
  • Alti-merkaptopuryna
  • Azatiopuryna
  • Bw 57-323H
  • Flocofil
  • Ismipur
  • Leukeryna
  • Leupuryna
  • Mercaleukim
  • Mercaleukin
  • Mercaptina
  • Merkaptopuryna
  • Merkapuryna
  • Mern
  • NCI-C04886
  • Puri-Nethol
  • Purymetol
  • Puryna, 6-merkapto-
  • Puryno-6-tiol (8CI)
  • Puryno-6-tiol, monohydrat
  • Purynotiol
  • U-4748
  • WR-2785

Given IV

Inne nazwy:
  • Medrol
  • Wyacort
  • Adlone
  • Caberdelta M
  • DepMedalone
  • Depo Moderin
  • Depo-Nisolon
  • Duralone
  • Emmetipi
  • Esameton
  • Firmacort
  • Medlone 21
  • Średnia
  • Medrol Veriderm
  • Medron
  • Mega-Gwiazda
  • Meprolon
  • Metyloprednizolon
  • Rozpuszczalny metylobetazon
  • Metrokort
  • Metyppresol
  • Metysolon
  • Predni-M-Tablin
  • Prednilen
  • Radiem
  • Sieropresol
  • Solpredon
  • Summicort
  • Urbason
  • Veriderm Medrol

Given IV

Inne nazwy:
  • Asparaginaza (Escherichia coli Isoenzyme II), Koniugat z alfa-(((2,5-diokso-1-pirolidynylo)oksy)karbonylo)-omega-metoksypoli(oksy-1,2-etanodiylem)
  • Szparagi
  • EZN-2285
  • SC-PEG E. Coli L-asparaginaza
  • Węglan sukcynimidylu Glikol monometoksypolietylenowy E. coli L-asparaginaza
  • Calaspargase Pegol-mknl

Given PO or IV

Inne nazwy:
  • Wellcovorin
  • kwas folinowy
  • Adinepar
  • Kalcyfolina
  • Wapń (6S)-folinian
  • Folinian wapnia
  • Leukoworyna wapnia
  • Calfolex
  • Kalinat
  • Cehafolin
  • Citofolina
  • Citrec
  • Czynnik Citrovorum
  • Cromatonbic Folinico
  • Dalisol
  • Dezintoksykacja
  • Divical
  • Ecofol
  • Emovis
  • Czynnik, Citrovorum
  • Flynoken A
  • Folaren
  • Folaksyna
  • Komórka FOLI
  • Foliben
  • Folidan
  • Folidar
  • Folinac
  • Pentahydrat soli wapniowej kwasu foliowego
  • Folinoral
  • Folinvit
  • Foliplus
  • Folix
  • Imo
  • Lederfolat
  • Lederfolin
  • Leukozar
  • leukoworyna
  • Reskufolina
  • Reskuwolina
  • Tonofolina

Given IT

Inne nazwy:
  • Abitreksat
  • Folex
  • Mikstura
  • MTX
  • Alfa-metopteryna
  • Ametopteryna
  • Brimeksat
  • CL 14377
  • CL-14377
  • Emteksat
  • Emthexat
  • Farmitreksat
  • Fauldexato
  • Folex PFS
  • Lantarel
  • Ledertreksat
  • Lumekson
  • Maxtrex
  • Medsatreksat
  • Metex
  • Metoblastyna
  • Metotreksat LPF
  • Metotreksat Metyloaminopteryna
  • Metotreksat
  • Metrotex
  • Mexate-AQ
  • Novatrex
  • Reumatreks
  • Texate
  • Tremetex
  • Trexeron
  • Trixilem
  • WR-19039
  • Jylamvo

Given IV, SC, or IT

Inne nazwy:
  • .beta.-arabinozyd cytozyny
  • 1-β.-D-Arabinofuranozylo-4-amino-2(1H)pirymidynon
  • 1-β.-D-Arabinofuranozylocytozyna
  • 1-Beta-D-arabinofuranozylo-4-amino-2(1H)pirymidynon
  • 1-Beta-D-arabinofuranozylocytozyna
  • 1.beta.-D-Arabinofuranozylocytozyna
  • 2(1H)-pirymidynon, 4-amino-1-beta-D-arabinofuranozylo-
  • 2(1H)-pirymidynon, 4-amino-1.beta.-D-arabinofuranozylo-
  • Alexan
  • Ara-C
  • Komórka ARA
  • Arabska
  • Arabinofuranozylocytozyna
  • Arabinozylocytozyna
  • Aracytydyna
  • Aracytyna
  • Arabinozyd beta-cytozyny
  • CHX-3311
  • Cytarabina
  • Cytarbel
  • Cytosar
  • Arabinozyd cytozyny
  • Cytozyno-β-arabinozyd
  • Cytozyna-beta-arabinozyd
  • Erpalfa
  • Starasid
  • Tarabina PFS
  • U 19920
  • U-19920
  • Udicil
  • WR-28453

Given PO or IV

Inne nazwy:
  • Dekadron
  • Hemady
  • Aacydeksam
  • Adekson
  • Aknichthol Dexa
  • Alba-Dex
  • Alin
  • Alin Depot
  • Alin Oftalmico
  • Ampliderma
  • Anemul mono
  • Uszny
  • Auksylozon
  • Bajkadron
  • Baycuten
  • Baycuten N
  • Kortydeksazon
  • Cortisumman
  • Dekokort
  • Dekadrol
  • Dekadron DP
  • Dekaliks
  • Dekamet
  • Dekazon R.p.
  • Dektanl
  • Dekacort
  • Deltafluoren
  • Deronil
  • Dezametazon
  • Desameton
  • Dexa-Mamallet
  • Dexa-Rhinosan
  • Dexa-Scheroson
  • Deksa-sinus
  • Deksakortal
  • Deksakortyna
  • Dexafarma
  • Deksafluoren
  • Deksalokalny
  • Deksamekortyna
  • Deksamet
  • Deksametazon Intensol
  • Deksametazon
  • Deksamonozon
  • Deksapos
  • Dexinoralny
  • Dekson
  • Dinormon
  • Dxevo
  • Fluorodelta
  • Fortekortyna
  • Gammacorten
  • Heksadekadrol
  • Heksadrol
  • Lokalizacja-F
  • Loverine
  • Metylofluorprednizolon
  • Millicorten
  • Mymetazon
  • Orgadron
  • Spersadex
  • TaperDex
  • Wisumetazon
  • ZoDex
  • LenaDex

Given IV

Inne nazwy:
  • Kardioksan
  • Totect
  • Zinecard

Given PO

Inne nazwy:
  • Gleevec
  • CGP 57148
  • CGP57148B
  • Glivec
  • STI 571
  • STI-571
  • STI571
  • CGP-57148B
  • CGP 57148B
  • CGP-57148
  • CGP57148
  • Imarech
  • Imat
  • Imkeldi

Given PO or IV

Inne nazwy:
  • Kwas lewofolinowy
  • Lewofolinian
  • CL-307 782
  • Elvorine, izovorin, lewofolen, levorin
  • Isovorin
  • L-leuocoworin
  • Khapzory

Given IV

Inne nazwy:
  • L-asparaginaza z glikolem polietylenowym
  • Oncaspar
  • Oncaspar IV
  • PEG-asparaginaza
  • PEG-L-asparaginaza
  • PEG-L-asparaginaza (Enzon - Kyowa Hakko)
  • PEGLA
  • L-asparaginaza glikolu polietylenowego

Given PO

Inne nazwy:
  • (11beta)-11,17,21-Trihydroksypregna-1,4-dien-3,20-dion
  • .delta.1-Hydrokortyzon
  • Adnizolon
  • Aprednislon
  • Kapsoid
  • Kortalon
  • Kortyzolon
  • Dakortyna H
  • Dekaprednil
  • Decortin H
  • Delta(1)Hydrokortyzon
  • Delta- Cortef
  • Delta-Cortef
  • Delta-Diona
  • Delta-F
  • Delta-forikol
  • Delta1-dehydrohydrokortyzon
  • Deltakortryl
  • Deltahydrokortyzon
  • Deltasolon
  • Deltidrozol
  • Dhasolon
  • Di-Adreson-F
  • Dontisolon D
  • Estilsona
  • Fisopred
  • Frisolona
  • Gupizon
  • Hostakortyna H
  • Hydeltra
  • Hydeltrazol
  • Klismacort
  • Kuhlprednon
  • Lenizolon
  • Lepi-Cortinolo
  • Linola-H N
  • Linola-H-Fett N
  • Longiprednil
  • Metakortandralon
  • Meti Derm
  • Metykortelon
  • Opredson
  • Panafkortelon
  • Prekortyzyl
  • Pred-Clysma
  • Predeltilon
  • Predni-Coelin
  • Predni-Helvacort
  • Prednikortelon
  • Prednizolon
  • Prelone
  • Prenilon
  • Sterane

Given PO

Inne nazwy:
  • 6-TG
  • 2-amino 6MP
  • 2-amino-1,7-dihydro-6H-puryno-6-tion
  • 2-amino-6-merkaptopuryna
  • 2-amino-6-purynotiol
  • 2-aminopuryno-6-tiol
  • 2-aminopuryno-6(1H)-tion
  • Półwodzian 2-aminopuryno-6-tiolu
  • 2-Merkapto-6-aminopuryna
  • 6-amino-2-merkaptopuryna
  • 6-Merkapto-2-aminopuryna
  • 6-Merkaptoguanina
  • 6H-Puryn-6-tion, 2-amino-1,7-dihydro- (9CI)
  • BW 5071
  • Lanvis
  • Tabletka
  • Półwodzian tioguaniny
  • Hydrat tioguaniny
  • Tioguanin
  • Tioguanina
  • Witaj U3B
  • WR-1141
  • X 27
Eksperymentalny: Arm C (imatinib mesylate, EsPhALL chemotherapy, HSCT)

See Detailed Description

Correlative studies

Given IV

Inne nazwy:
  • Cytoksan
  • CTX
  • (-)-cyklofosfamid
  • 2H-1,3,2-Oksazafosforyna, 2-[bis(2-chloroetylo)amino]tetrahydro-, 2-tlenek, monohydrat
  • Karloksan
  • Cyklofosfamida
  • Cyklofosfamid
  • Cykloksal
  • Clafen
  • Klafen
  • Monohydrat CP
  • Ogniwo CYCLO
  • Cykloblastyna
  • Cyklofosfam
  • Monohydrat cyklofosfamidu
  • Cyklofosfan
  • Cyklostyna
  • Cytofosfan
  • Fosfaseron
  • Genoksal
  • Genuxal
  • Ledoksyna
  • Mitoksan
  • Neosar
  • Revimmune
  • Syklofosfamid
  • WR-138719
  • Asta B 518
  • B-518
  • B518
  • WR 138719
  • WR138719
  • Frindovyx

Given IV

Inne nazwy:
  • Adriablastyna
  • Hydroksydaunomycyna
  • Hydroksylowa daunorubicyna
  • Hydroksyldaunorubicyna

Given IV

Inne nazwy:
  • Oncovin
  • Kyocristine
  • Siarczan Leurokrystyny
  • Leurokrystyna, siarczan
  • Vincasar
  • Vincosid
  • Vincrex
  • Winkrystyna, siarczan

Ancillary studies

Given IV

Inne nazwy:
  • Cerubidyna
  • Cloridrato de Daunorubicina
  • Daunoblastyna
  • Daunoblastina
  • Chlorowodorek daunomycyny
  • Daunomycyna, chlorowodorek
  • Chlorowodorek daunorubicyny
  • Daunorubicini Hydrochloridum
  • FI-6339
  • Ondena
  • RP-13057
  • Chlorowodorek rubidomycyny
  • Rubilem

Given IV

Inne nazwy:
  • Demetylo Epipodofilotoksyna Glukozyd etylidyny
  • EPEG
  • Ostatnie
  • Toposar
  • Vepesid
  • WP 16
  • VP 16-213
  • VP-16
  • VP-16-213
  • VP16
  • VP 16213
  • VP-16213
  • VP16213

Given PO

Inne nazwy:
  • 6-MP
  • Purynetol
  • 3H-Puryn-6-tiol
  • 6 MP
  • 6 Tiohipoksantyna
  • 6 Tiopuryna
  • 6-Merkaptopuryna
  • Monohydrat 6-merkaptopuryny
  • 6-purinetiol
  • 6-Tiopuryna
  • 6-tioksopuryna
  • 6H-Puryn-6-tion, 1,7-dihydro- (9CI)
  • 7-merkapto-1,3,4,6-tetrazainden
  • Alti-merkaptopuryna
  • Azatiopuryna
  • Bw 57-323H
  • Flocofil
  • Ismipur
  • Leukeryna
  • Leupuryna
  • Mercaleukim
  • Mercaleukin
  • Mercaptina
  • Merkaptopuryna
  • Merkapuryna
  • Mern
  • NCI-C04886
  • Puri-Nethol
  • Purymetol
  • Puryna, 6-merkapto-
  • Puryno-6-tiol (8CI)
  • Puryno-6-tiol, monohydrat
  • Purynotiol
  • U-4748
  • WR-2785

Given IV

Inne nazwy:
  • Medrol
  • Wyacort
  • Adlone
  • Caberdelta M
  • DepMedalone
  • Depo Moderin
  • Depo-Nisolon
  • Duralone
  • Emmetipi
  • Esameton
  • Firmacort
  • Medlone 21
  • Średnia
  • Medrol Veriderm
  • Medron
  • Mega-Gwiazda
  • Meprolon
  • Metyloprednizolon
  • Rozpuszczalny metylobetazon
  • Metrokort
  • Metyppresol
  • Metysolon
  • Predni-M-Tablin
  • Prednilen
  • Radiem
  • Sieropresol
  • Solpredon
  • Summicort
  • Urbason
  • Veriderm Medrol

Given IV

Inne nazwy:
  • Asta Z 4942
  • Asta Z-4942
  • Cyfos
  • Holoksan
  • Ifex
  • IFO
  • Komórka IFO
  • Ifolem
  • Ifomida
  • Ifomid
  • Ifosfamid
  • Ifoksan
  • IFX
  • Izo-endoksan
  • Izoendoksan
  • Izofosfamid
  • Mitoksana
  • MJF 9325
  • MJF-9325
  • Naksamid
  • Seromida
  • Tronoxal
  • Z 4942
  • Z-4942

Given IV

Inne nazwy:
  • Asparaginaza (Escherichia coli Isoenzyme II), Koniugat z alfa-(((2,5-diokso-1-pirolidynylo)oksy)karbonylo)-omega-metoksypoli(oksy-1,2-etanodiylem)
  • Szparagi
  • EZN-2285
  • SC-PEG E. Coli L-asparaginaza
  • Węglan sukcynimidylu Glikol monometoksypolietylenowy E. coli L-asparaginaza
  • Calaspargase Pegol-mknl

Given PO or IV

Inne nazwy:
  • Wellcovorin
  • kwas folinowy
  • Adinepar
  • Kalcyfolina
  • Wapń (6S)-folinian
  • Folinian wapnia
  • Leukoworyna wapnia
  • Calfolex
  • Kalinat
  • Cehafolin
  • Citofolina
  • Citrec
  • Czynnik Citrovorum
  • Cromatonbic Folinico
  • Dalisol
  • Dezintoksykacja
  • Divical
  • Ecofol
  • Emovis
  • Czynnik, Citrovorum
  • Flynoken A
  • Folaren
  • Folaksyna
  • Komórka FOLI
  • Foliben
  • Folidan
  • Folidar
  • Folinac
  • Pentahydrat soli wapniowej kwasu foliowego
  • Folinoral
  • Folinvit
  • Foliplus
  • Folix
  • Imo
  • Lederfolat
  • Lederfolin
  • Leukozar
  • leukoworyna
  • Reskufolina
  • Reskuwolina
  • Tonofolina

Given IT

Inne nazwy:
  • Abitreksat
  • Folex
  • Mikstura
  • MTX
  • Alfa-metopteryna
  • Ametopteryna
  • Brimeksat
  • CL 14377
  • CL-14377
  • Emteksat
  • Emthexat
  • Farmitreksat
  • Fauldexato
  • Folex PFS
  • Lantarel
  • Ledertreksat
  • Lumekson
  • Maxtrex
  • Medsatreksat
  • Metex
  • Metoblastyna
  • Metotreksat LPF
  • Metotreksat Metyloaminopteryna
  • Metotreksat
  • Metrotex
  • Mexate-AQ
  • Novatrex
  • Reumatreks
  • Texate
  • Tremetex
  • Trexeron
  • Trixilem
  • WR-19039
  • Jylamvo

Given IV, SC, or IT

Inne nazwy:
  • .beta.-arabinozyd cytozyny
  • 1-β.-D-Arabinofuranozylo-4-amino-2(1H)pirymidynon
  • 1-β.-D-Arabinofuranozylocytozyna
  • 1-Beta-D-arabinofuranozylo-4-amino-2(1H)pirymidynon
  • 1-Beta-D-arabinofuranozylocytozyna
  • 1.beta.-D-Arabinofuranozylocytozyna
  • 2(1H)-pirymidynon, 4-amino-1-beta-D-arabinofuranozylo-
  • 2(1H)-pirymidynon, 4-amino-1.beta.-D-arabinofuranozylo-
  • Alexan
  • Ara-C
  • Komórka ARA
  • Arabska
  • Arabinofuranozylocytozyna
  • Arabinozylocytozyna
  • Aracytydyna
  • Aracytyna
  • Arabinozyd beta-cytozyny
  • CHX-3311
  • Cytarabina
  • Cytarbel
  • Cytosar
  • Arabinozyd cytozyny
  • Cytozyno-β-arabinozyd
  • Cytozyna-beta-arabinozyd
  • Erpalfa
  • Starasid
  • Tarabina PFS
  • U 19920
  • U-19920
  • Udicil
  • WR-28453

Given PO or IV

Inne nazwy:
  • Dekadron
  • Hemady
  • Aacydeksam
  • Adekson
  • Aknichthol Dexa
  • Alba-Dex
  • Alin
  • Alin Depot
  • Alin Oftalmico
  • Ampliderma
  • Anemul mono
  • Uszny
  • Auksylozon
  • Bajkadron
  • Baycuten
  • Baycuten N
  • Kortydeksazon
  • Cortisumman
  • Dekokort
  • Dekadrol
  • Dekadron DP
  • Dekaliks
  • Dekamet
  • Dekazon R.p.
  • Dektanl
  • Dekacort
  • Deltafluoren
  • Deronil
  • Dezametazon
  • Desameton
  • Dexa-Mamallet
  • Dexa-Rhinosan
  • Dexa-Scheroson
  • Deksa-sinus
  • Deksakortal
  • Deksakortyna
  • Dexafarma
  • Deksafluoren
  • Deksalokalny
  • Deksamekortyna
  • Deksamet
  • Deksametazon Intensol
  • Deksametazon
  • Deksamonozon
  • Deksapos
  • Dexinoralny
  • Dekson
  • Dinormon
  • Dxevo
  • Fluorodelta
  • Fortekortyna
  • Gammacorten
  • Heksadekadrol
  • Heksadrol
  • Lokalizacja-F
  • Loverine
  • Metylofluorprednizolon
  • Millicorten
  • Mymetazon
  • Orgadron
  • Spersadex
  • TaperDex
  • Wisumetazon
  • ZoDex
  • LenaDex

Given IV

Inne nazwy:
  • Kardioksan
  • Totect
  • Zinecard

Given SC or IV

Inne nazwy:
  • G-CSF
  • r-metHuG-CSF
  • Neupogen
  • Filgrastym-aafi
  • Nivestym
  • Rekombinowany metionylowy czynnik stymulujący tworzenie kolonii ludzkich granulocytów
  • rG-CSF
  • Tewagrastym
  • Filgrastim Biopodobny Filgrastim-sndz
  • Zarxio
  • Filgrastym XM02
  • Tbo-filgrastym
  • Granix
  • Nivestim
  • XM02
  • Filgrastim-sndz
  • Filgrastym Biopodobny Tbo-filgrastym
  • Filgrastym-ayow
  • Releuko
  • Neutroval

Given PO

Inne nazwy:
  • Gleevec
  • CGP 57148
  • CGP57148B
  • Glivec
  • STI 571
  • STI-571
  • STI571
  • CGP-57148B
  • CGP 57148B
  • CGP-57148
  • CGP57148
  • Imarech
  • Imat
  • Imkeldi

Given PO or IV

Inne nazwy:
  • Kwas lewofolinowy
  • Lewofolinian
  • CL-307 782
  • Elvorine, izovorin, lewofolen, levorin
  • Isovorin
  • L-leuocoworin
  • Khapzory

Given IV

Inne nazwy:
  • L-asparaginaza z glikolem polietylenowym
  • Oncaspar
  • Oncaspar IV
  • PEG-asparaginaza
  • PEG-L-asparaginaza
  • PEG-L-asparaginaza (Enzon - Kyowa Hakko)
  • PEGLA
  • L-asparaginaza glikolu polietylenowego

Given PO

Inne nazwy:
  • (11beta)-11,17,21-Trihydroksypregna-1,4-dien-3,20-dion
  • .delta.1-Hydrokortyzon
  • Adnizolon
  • Aprednislon
  • Kapsoid
  • Kortalon
  • Kortyzolon
  • Dakortyna H
  • Dekaprednil
  • Decortin H
  • Delta(1)Hydrokortyzon
  • Delta- Cortef
  • Delta-Cortef
  • Delta-Diona
  • Delta-F
  • Delta-forikol
  • Delta1-dehydrohydrokortyzon
  • Deltakortryl
  • Deltahydrokortyzon
  • Deltasolon
  • Deltidrozol
  • Dhasolon
  • Di-Adreson-F
  • Dontisolon D
  • Estilsona
  • Fisopred
  • Frisolona
  • Gupizon
  • Hostakortyna H
  • Hydeltra
  • Hydeltrazol
  • Klismacort
  • Kuhlprednon
  • Lenizolon
  • Lepi-Cortinolo
  • Linola-H N
  • Linola-H-Fett N
  • Longiprednil
  • Metakortandralon
  • Meti Derm
  • Metykortelon
  • Opredson
  • Panafkortelon
  • Prekortyzyl
  • Pred-Clysma
  • Predeltilon
  • Predni-Coelin
  • Predni-Helvacort
  • Prednikortelon
  • Prednizolon
  • Prelone
  • Prenilon
  • Sterane

Given IT

Inne nazwy:
  • Aeroseb-HC
  • Barseb HC
  • Barseb-HC
  • Cetacort
  • Cort-Dome
  • Cortef
  • Cortenema
  • Cortifan
  • Kortyzol
  • Cortispray
  • Kortril
  • Dermacort
  • Domolen
  • Eldecort
  • Hautosone
  • Heb-Cort
  • Hydrokortyzon
  • Hydrokorton
  • Hiton
  • Komed-HC
  • Nutracort
  • Proctocort
  • Prostokątny

Given PO

Inne nazwy:
  • 6-TG
  • 2-amino 6MP
  • 2-amino-1,7-dihydro-6H-puryno-6-tion
  • 2-amino-6-merkaptopuryna
  • 2-amino-6-purynotiol
  • 2-aminopuryno-6-tiol
  • 2-aminopuryno-6(1H)-tion
  • Półwodzian 2-aminopuryno-6-tiolu
  • 2-Merkapto-6-aminopuryna
  • 6-amino-2-merkaptopuryna
  • 6-Merkapto-2-aminopuryna
  • 6-Merkaptoguanina
  • 6H-Puryn-6-tion, 2-amino-1,7-dihydro- (9CI)
  • BW 5071
  • Lanvis
  • Tabletka
  • Półwodzian tioguaniny
  • Hydrat tioguaniny
  • Tioguanin
  • Tioguanina
  • Witaj U3B
  • WR-1141
  • X 27

Undergo HSCT

Inne nazwy:
  • Allogeniczne
  • Transplantacja allogenicznych komórek krwiotwórczych
  • Allogeniczny przeszczep komórek macierzystych
  • HSC
  • HSCT
  • Przeszczep komórek macierzystych, allogeniczny

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Disease free survival (DFS) of Randomized Arms (standard risk [SR] Philadelphia chromosome [Ph+] acute lymphoblastic leukemia [ALL] patients)
Ramy czasowe: Up to 3 years

Three-year DFS and 95% confidence intervals (CI) of SR Ph+ ALL patients treated continuous imatinib mesylate with high risk Children's Oncology Group (COG)-ALL chemotherapy backbone or more intensive European (Es)PhALL chemotherapy backbone.

Up to 3 years

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
DFS on Randomized Arms (SR Ph+ ALL and ABL-class fusion positive patients)
Ramy czasowe: Up to 3 years

Three-year DFS (time from randomization to relapse, second malignancy, or death in complete remission) and 95% CI of SR pediatric Ph+ and ABL-class fusion positive patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone.

Up to 3 years
Feasibility of post hematopoietic stem cell transplantation (HSCT) imatinib mesylate administration after allogenic HSCT in high risk Ph+ ALL patients
Ramy czasowe: Up to 2 years

The proportion of patients who receive at least 75% of intended doses.

Up to 2 years
Event free survival (EFS) of high risk pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission, and post-HSCT imatinib mesylate
Ramy czasowe: Up to 3 years

Three-year EFS and 95% CI for high risk pediatric Ph+ ALL patients treated with EsPhALL chemotherapy, HSCT in first complete remission, and post-HSCT imatinib mesylate. EFS is defined as the time from the date of bone marrow for minimal residual disease (MRD) assessment at end-IB to first event (resistant disease [MRD >= 10-2 or morphologic residual disease at end of consolidation block 3], relapse, progressive disease [i.e., MRD >= 10-2 at two post-HSCT time points separated by at least 2 weeks], second malignancy, or death in complete remission), or time to last follow-up for patients without events.

Up to 3 years
Incidence of grade 3 or higher infections in standard risk Ph+ ALL patients in the two randomized arms
Ramy czasowe: Up to 3 years

Evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The rate of infections during the post IB/pre-maintenance phases of treatment will be described for each randomization group.

Up to 3 years
EFS of all Ph+ patients
Ramy czasowe: Up to 3 years

Three-year EFS and 95% CI for Ph+ ALL patients. EFS here is defined as the time from enrollment until resistant disease, relapse, progressive disease post-HSCT, second malignant, or death, whichever occurs first.

Up to 3 years
Overall survival (OS) of all Ph+ patients
Ramy czasowe: Up to 3 years

Three-year OS and 95% CI for Ph+ ALL patients. OS is defined as the time from study enrollment to death from any cause.

Up to 3 years
OS of SR Ph+ patients
Ramy czasowe: Up to 3 years

Three-year OS (time from randomization to death from any cause) and 95% CI of SR pediatric Ph+ patients

Up to 3 years
OS of SR Ph+ patients by randomization group
Ramy czasowe: Up to 3 years

Three-year OS (time from randomization to death from any cause) and 95% CI of SR pediatric Ph+ patients by randomization group: treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone.

Up to 3 years
OS of high risk Ph+ patients
Ramy czasowe: Up to 3 years

Three-year OS (time from the date of MRD assessment at end-IB to death from any cause) and 95% CI of HR pediatric Ph+ patients.

Up to 3 years
EFS of all eligibility ABL-class fusion positive ALL patients
Ramy czasowe: Up to 3 years

Three-year EFS (time from enrollment until resistant disease, relapse, progressive disease post-HSCT, second malignancy, or death, whichever occurs first) and 95% CI of ABL-class fusion positive patients.

Up to 3 years
OS of all eligibility ABL-class fusion positive ALL patients
Ramy czasowe: Up to 3 years

Three-year OS (the time from study enrollment to death from any cause) and 95% CI of ABL-class fusion positive patients.

Up to 3 years

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Incidence of toxicities associated with post-HSCT administration of imatinib mesylate
Ramy czasowe: Up to 2 years

Evaluated according to NCI CTCAE version 5.0. Frequencies of target toxicities in high risk patients after the initiation of post-HSCT imatinib mesylate will be described. For the high risk patients, the specific targeted toxicities will include grade 4 neutropenia, grade 4 thrombocytopenia, grade 3 or higher bilirubin, grade 4 or higher transaminitis, and grade 3 or higher infection.

Up to 2 years
Incidence of long-term toxicities in patients treated with chemotherapy plus imatinib mesylate (no transplant) in both arms
Ramy czasowe: Up to 3 years

Evaluated according to NCI CTCAE version 5.0. Frequencies of long-term toxicities will be described and differences between randomized arms will be explored. Specific long-term toxicities to be explored include cardiac (echocardiographic abnormalities, including decreased left ventricular (LV) function and decreased LV wall thickness), growth (linear height, bone age), and second malignant neoplasm.

Up to 3 years
MRD measured by IGH-T cell receptor (TCR) polymerase chain reaction (PCR) and next generation sequencing (NGS) assay
Ramy czasowe: Up to 6 months

For all patients, frequencies and prognostic significance (DFS, EFS, OS) will be explored for MRD levels (i.e., MRD negative, detectable at < 5 x 10^-4, and dectectable at >= 5 x 10^-4) at end of Induction IB.

Up to 6 months
MRD in high risk Ph+ patients measured by IGH-TCR PCR and NGS assay
Ramy czasowe: Up to 3 years

The outcome of high risk Ph+ patients will be described, including proportion of patients who achieve MRD-negativity just prior to HSCT, and at regular intervals post-HSCT. Associations between these findings and long-term outcomes (e.g., OS, DFS) will be explored.

Up to 3 years
MRD assessments made by IGH-TCR PCR assay and NGS assay
Ramy czasowe: Up to 3 years

Concordance of MRD assessments made by IGH-TCR PCR assay and NGS assay will be described and evaluated. Scatter plots and diagrams will be used to examine agreements and patterns of agreement or any differences found. Concordance will be explored both for the overall cohort, as well as by risk group. The increased sensitivity of the NGS will be closely examined to find cases where the MRD levels are detectable by NGS but undetectable by PCR, as well as cases in which one test yields results and the other does not (test failure). Prognostic relationships on outcomes for these subjects will be inspected.

Up to 3 years
IKZF1 deletions alone
Ramy czasowe: Up to 3 years

Will determine and validate if IKZF1 deletions alone predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631.

Up to 3 years
IKZF1 deletions with other transcription factor deletions
Ramy czasowe: Up to 3 years

Will determine and validate if IKZF1 deletions with other transcription factor deletions predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631.

Up to 3 years
Other identified genetic lesions
Ramy czasowe: Up to 3 years

Will determine and validate if other identified genetic lesions predict poor outcomes in Ph+/ABL-class Ph-like ALL in patients treated on AALL1631.

Up to 3 years
Frequency of p190 and p210 BCR::ABL1 fusion variants
Ramy czasowe: Up to 3 years

For both standard risk and high risk groups, frequencies and prognostic significance (OS, DFS) will be explored for p190 and p210 BCR::ABL1 fusion variants in pediatric Ph+ ALL/ABL-class Ph-like ALL.

Up to 3 years
Adherence to oral chemotherapeutic agents in standard risk Ph+ ALL patients
Ramy czasowe: Up to 2 years

Adherence to imatinib mesylate, 6-mercaptopurine, and methotrexate will be evaluated in COG-enrolled participants using an electronic monitoring device. Adherence rate will be computed for each month of adherence monitoring. Longitudinal binomial regression will be conducted using generalized estimating equation methods by modeling monthly adherence rate as an unstructured mean model using five indicator variables of time for the study months. Time in months will also be treated as a continuous variable to explore temporal trends in adherence rate. Compound symmetry will be assumed as the working correlation matrix over time. Covariates that will be considered for adjustment include those hypothesized to be predictors of adherence, annual household income, parental education, time since start of maintenance, risk classification for ALL, and imatinib, 6-mercaptopurine (6MP), and methotrexate dose-intensity.

Up to 2 years
Adherence to imatinib mesylate after allogeneic HSCT in high risk Ph+ ALL patients
Ramy czasowe: Up to 2 years

Longitudinal binomial regression will be conducted using generalized estimating equation methods by modeling monthly adherence rate as an unstructured mean model using five indicator variables of time for the study months. Time in months will also be treated as a continuous variable to explore temporal trends in adherence rate. Compound symmetry will be assumed as the working correlation matrix over time. Covariates that will be considered for adjustment include those hypothesized to be predictors of adherence, annual household income, parental education, time since start of maintenance, risk classification for ALL, and imatinib, 6MP, and methotrexate dose-intensity.

Up to 2 years
DFS of SR ABL-class fusion positive patients
Ramy czasowe: Up to 3 years

Three-year DFS (time from randomization to relapse, second malignancy, or death in complete remission) and 95% CI of SR pediatric ABL-class fusion positive patients treated with continuous imatinib combined with either a high-risk COG-ALL chemotherapy backbone or the more intensive EsPhALL chemotherapy backbone.

Up to 3 years
Secondary and exploratory aims applied to ABL-class fusion positive patients
Ramy czasowe: Up to 3 years

Secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable, will be evaluated in ABL-class fusion positive ALL patients.

Up to 3 years
Therapeutic impact of major secondary events
Ramy czasowe: Up to 3 years

Will determine the potential therapeutic impact of major secondary events via pharmacologic inhibitor screens in existing/engineered cell models of Ph+ and ABL-class Ph-like ALL harboring secondary events.

Up to 3 years
Secondary and exploratory aims applied to super-set of Ph+ and ABL-class fusion positive patients
Ramy czasowe: Up to 3 years

Secondary and exploratory aims described above for Ph+ ALL patients (either SR or HR), if applicable, will be evaluated in the superset of Ph+ and ABL-class fusion positive ALL patients.

Up to 3 years
In vivo activity
Ramy czasowe: Up to 3 years

Will test the in vivo activity of the most compelling candidate compounds from pilot studies using patient-derived xenograft models established from Ph+ and ABL-class Ph-like ALL samples collected from patients treated on AALL1631.

Up to 3 years
Molecular heterogeneity
Ramy czasowe: Up to 3 years

Will decipher the molecular heterogeneity of chronic myelogenous leukemia (CML)-like versus typical Ph+ ALL via single-cell genomics and functional assays.

Up to 3 years
Cellular heterogeneity
Ramy czasowe: Up to 3 years

Will decipher the cellular heterogeneity of CML-like versus typical Ph+ ALL via single-cell genomics and functional assays.

Up to 3 years
CML-like phenotypes
Ramy czasowe: Up to 3 years

Will investigate CML-like phenotypes via single-cell ribonucleic acid and deoxyribonucleic acid sequencing to identify distinct transcriptomic and mutational profiles that will provide novel opportunities for diagnostic and therapeutic interventions.

Up to 3 years

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Lewis B Silverman, Children's Oncology Group
  • Główny śledczy: Andrea Biondi, EsPhALL Network/ BFM Study Group

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

8 sierpnia 2017

Zakończenie podstawowe (Rzeczywisty)

30 czerwca 2026

Ukończenie studiów (Szacowany)

30 września 2034

Daty rejestracji na studia

Pierwszy przesłany

28 grudnia 2016

Pierwszy przesłany, który spełnia kryteria kontroli jakości

28 grudnia 2016

Pierwszy wysłany (Szacowany)

2 stycznia 2017

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

5 października 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

30 września 2026

Ostatnia weryfikacja

1 września 2026

Więcej informacji

Terminy związane z tym badaniem

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • AALL1631
  • U10CA180886 (Grant/umowa NIH USA)
  • 2017 (Grant/umowa NIH USA)
  • AALL1631 (Inny identyfikator: CTEP)
  • NCI-2016-01588 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
  • 2017-000705-20
  • 2024-515499-12-00
  • AALL1631 (Inny identyfikator: Children's Oncology Group)
  • 2017-000705-20 (Numer EudraCT)
  • 2024-515499-12-00 (Ctis)

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj